Data were taken from the literature; hence, ethical approval is not required.
Consent to participate
Not applicable.
Consent to publication
Not applicable.
Availability of data and materials
All data supporting the findings of this study are available within the manuscript and its cited references. Further analytical data are available from the corresponding author upon reasonable request.
Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.
References
Tegenge MA, Mahmood I, Struble EB, Sauna Z. Pharmacokinetics of antibodies during pregnancy: General pharmacokinetics and pregnancy related physiological changes (Part 1).Int Immunopharmacol. 2023;117:109914. [DOI] [PubMed]
Costantine MM. Physiologic and pharmacokinetic changes in pregnancy.Front Pharmacol. 2014;5:65. [DOI] [PubMed] [PMC]
Muñoz Z. Physiology of pregnancy [Internet].[cited 2024 Jul]. Available from: www.merckmanuals.com
Sanghavi M, Rutherford JD. Cardiovascular physiology of pregnancy.Circulation. 2014;130:1003–8. [DOI] [PubMed]
Moya J, Phillips L, Sanford J, Wooton M, Gregg A, Schuda L. A review of physiological and behavioral changes during pregnancy and lactation: potential exposure factors and data gaps.J Expo Sci Environ Epidemiol. 2014;24:449–58. [DOI] [PubMed]
Abduljalil K, Furness P, Johnson TN, Rostami-Hodjegan A, Soltani H. Anatomical, physiological and metabolic changes with gestational age during normal pregnancy: a database for parameters required in physiologically based pharmacokinetic modelling.Clin Pharmacokinet. 2012;51:365–96. [DOI] [PubMed]
Allegaert K, Quinney SK, Dallmann A. Physiologically Based Pharmacokinetic Modeling in Pregnancy, during Lactation and in Neonates: Achievements, Challenges and Future Directions.Pharmaceutics. 2024;16:500. [DOI] [PubMed] [PMC]
Thepaut E, Brochot C, Chardon K, Persone S, Zeman F. Pregnancy-PBPK models: How are biochemical and physiological processes integrated?Comput Toxicol. 2023;27:100282. [DOI]
Björkman S. Reduction and lumping of physiologically based pharmacokinetic models: prediction of the disposition of fentanyl and pethidine in humans by successively simplified models.J Pharmacokinet Pharmacodyn. 2003;30:285–307. [DOI] [PubMed]
Cao Y, Jusko WJ. Applications of minimal physiologically-based pharmacokinetic models.J Pharmacokinet Pharmacodyn. 2012;39:711–23. [DOI] [PubMed] [PMC]
Cao Y, Balthasar JP, Jusko WJ. Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies.J Pharmacokinet Pharmacodyn. 2013;40:597–607. [DOI] [PubMed] [PMC]
Zhao J, Cao Y, Jusko WJ. Across-Species Scaling of Monoclonal Antibody Pharmacokinetics Using a Minimal PBPK Model.Pharm Res. 2015;32:3269–81. [DOI] [PubMed] [PMC]
Mahmood I. A GFR-Based Method to Predict the Effect of Renal Impairment on the Exposure or Clearance of Renally Excreted Drugs: A Comparative Study Between a Simple GFR Method and a Physiologically Based Pharmacokinetic Model.Drugs R D. 2020;20:377–87. [DOI] [PubMed] [PMC]
Mahmood I. Prediction of drug exposure in hepatic impairment: a comparison between minimal physiologically based pharmacokinetic (mPBPK) and whole body PBPK models.Explor Drug Sci. 2025;3:100894. [DOI]
Xia B, Heimbach T, Gollen R, Nanavati C, He H. A simplified PBPK modeling approach for prediction of pharmacokinetics of four primarily renally excreted and CYP3A metabolized compounds during pregnancy.AAPS J. 2013;15:1012–24. [DOI] [PubMed] [PMC]
Song L, Yu Z, Xu Y, Li X, Liu X, Liu D, et al. Preliminary physiologically based pharmacokinetic modeling of renally cleared drugs in Chinese pregnant women.Biopharm Drug Dispos. 2020;41:248–67. [DOI] [PubMed]
Abduljalil K, Pansari A, Ning J, Jamei M. Prediction of Maternal and Fetal Acyclovir, Emtricitabine, Lamivudine, and Metformin Concentrations during Pregnancy Using a Physiologically Based Pharmacokinetic Modeling Approach.Clin Pharmacokinet. 2022;61:725–48. [DOI] [PubMed]
Dallmann A, Ince I, Solodenko J, Meyer M, Willmann S, Eissing T, et al. Physiologically Based Pharmacokinetic Modeling of Renally Cleared Drugs in Pregnant Women.Clin Pharmacokinet. 2017;56:1525–41. [DOI] [PubMed]
Coppola P, Kerwash E, Cole S. The Use of Pregnancy Physiologically Based Pharmacokinetic Modeling for Renally Cleared Drugs.J Clin Pharmacol. 2022;62 Suppl 1:S129–39. [DOI] [PubMed]
Pillai VC, Han K, Beigi RH, Hankins GD, Clark S, Hebert MF, et al. Population pharmacokinetics of oseltamivir in non-pregnant and pregnant women.Br J Clin Pharmacol. 2015;80:1042–50. [DOI] [PubMed] [PMC]
De Sousa Mendes M, Hirt D, Urien S, Valade E, Bouazza N, Foissac F, et al. Physiologically-based pharmacokinetic modeling of renally excreted antiretroviral drugs in pregnant women.Br J Clin Pharmacol. 2015;80:1031–41. [DOI] [PubMed] [PMC]
Colbers APH, Hawkins DA, Gingelmaier A, Kabeya K, Rockstroh JK, Wyen C, et al. The pharmacokinetics, safety and efficacy of tenofovir and emtricitabine in HIV-1-infected pregnant women.AIDS. 2013;27:739–48. [DOI] [PubMed]
Tegenge MA, Mahmood I, Struble EB, Sauna Z. Pharmacokinetics of antibodies during Pregnancy: Impact of pregnancy on the pharmacokinetics of antibodies (Part 2).Int Immunopharmacol. 2023;119:109915. [DOI] [PubMed]
Mahmood I, Li Z. Immunoglobulin therapies for primary immunodeficiency diseases (part 1): understanding the pharmacokinetics.Immunotherapy. 2024;16:879–94. [DOI] [PubMed] [PMC]
